## nature portfolio

Corresponding author(s):	Carla Grandori
Last updated by author(s):	15 Feb 2023

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

_				
C -	トつ	+1	ct.	ics
	п		<b>``</b>	11 >

For	all statistical an	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a	Confirmed					
$\boxtimes$	The exact	sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement				
$\times$	A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
$\boxtimes$		tical test(s) used AND whether they are one- or two-sided non tests should be described solely by name; describe more complex techniques in the Methods section.				
$\boxtimes$	A descript	cion of all covariates tested				
$\boxtimes$	A descript	cion of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
		cription of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) tion (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
$\boxtimes$		ypothesis testing, the test statistic (e.g. $F$ , $t$ , $r$ ) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted es as exact values whenever suitable.				
$\boxtimes$	For Bayes	ian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
$\times$	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes					
$\times$	Estimates	of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated				
	ı	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				
So	ftware an	d code				
Poli	cy information	about <u>availability of computer code</u>				
Da	ata collection	Provide a description of all commercial, open source and custom code used to collect the data in this study, specifying the version used OR				

Provide a description of all commercial, open source and custom code used to analyse the data in this study, specifying the version used OR

## reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Data analysis

Policy information about <u>availability of data</u>

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and

- Accession codes, unique identifiers, or web links for publicly available datasets

state that no software was used.

state that no software was used.

- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The authors declare that data supporting the findings of this study are available within the article and its supplementary information files.

Human rese	arch part	icipants			
Policy information	about <u>studies</u>	involving human research participants and Sex and Gender in Research.			
Reporting on sex	and gender	na			
Population chara		na			
Recruitment		na			
Ethics oversight	ation on the ann	Identify the organization(s) that approved the study protocol.  roval of the study protocol must also be provided in the manuscript.			
Note that full illioning	ation on the app	oval of the study protocormust also be provided in the manuscript.			
Field-spe	ecific re	norting			
<u>.</u>		is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
X Life sciences		Behavioural & social sciences Ecological, evolutionary & environmental sciences			
For a reference copy of	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Life scier	nces st	udy design			
All studies must dis	sclose on these	e points even when the disclosure is negative.			
Sample size		cribe how sample size was determined, detailing any statistical methods used to predetermine sample size OR if no sample-size calculation sperformed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.			
Data exclusions		any data exclusions. If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the behind them, indicating whether exclusion criteria were pre-established.			
Replication		Describe the measures taken to verify the reproducibility of the experimental findings. If all attempts at replication were successful, confirm this OR if there are any findings that were not replicated or cannot be reproduced, note this and describe why.			
Randomization		Describe how samples/organisms/participants were allocated into experimental groups. If allocation was not random, describe how covariates were controlled OR if this is not relevant to your study, explain why.			
Blinding	Describe whether the investigators were blinded to group allocation during data collection and/or analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.				
	6				
		pecific materials, systems and methods			
		about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, by your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.			
Materials & experimental systems Methods					
n/a Involved in th	ne study	n/a Involved in the study			
Antibodies	5	ChIP-seq			
Eukaryotic	cell lines	Flow cytometry			
	logy and archaed				
Animals and other organisms					
Clinical data					
Dual use research of concern					